Landcadia Holdings IV, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Landcadia Holdings IV, Inc. operated as a special purpose acquisition company, or SPAC, established with the aim of merging, exchanging capital stock, acquiring assets, purchasing stock, reorganizing, or engaging in similar business combinations with one or more enterprises. Its strategic focus was directed toward opportunities within the consumer, dining, hospitality, entertainment, and gaming sectors. The company, which was formerly known as JFG Holding I LLC, was formed in 2020 and maintained its corporate base in Houston, Texas. However, Landcadia Holdings IV, Inc. ultimately determined it would not complete a business combination and subsequently announced the redemption of its public shares, with shareholders receiving $10.56 per share. The public shares were canceled, and the company was delisted in February 2024.
Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program
Opus Genetics: Asymmetric Upside With LCA5 And BEST1
Beyond Meat® Releases 2024 Corporate Responsibility Report and LCA Study that Estimates Environmental Benefits of Beyond Burger® IV, Submits to CDP for First Time
Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease
Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)
Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate
Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision
Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases
Opus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting
Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program
Beyond Meat® Releases 2023 ESG Report and LCA Study that Estimates Environmental Benefits of Beyond Steak® Plant-Based Seared Tips When Compared to Pre-Cooked Beef-Based Steak Tips
Segway-Ninebot Goes Green with Electric KickScooters and More Sustainable Practices
Last Chance for Animals, Animal Liberation Wave Undercover Investigation Unveils More Atrocities in South Korean Dog Meat Trade
Life Cycle Assessment (LCA) Study in India Shows that Aluminium Beverage Cans have Superior Environmental Performance over Glass, PET and Multi-layer Drinks Containers
Landcadia Holdings III, Inc. (LCY) CEO Doug Cahill on Q1 2021 Results - Earnings Call Transcript
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Landcadia Holdings III, Inc. - LCY
A Smooth Transition Is Great News For Landcadia Holdings II
Landcadia Holdings II Stock Is Looking Like a Golden Nugget
3 of the Top Performing SPACs in 2020
The Easy Case for Landcadia Holdings II Stock Isn't Quite So Easy